MRI and PET/MRI in hematologic malignancies

Mayerhoefer, Marius E.; Archibald, Stephen J.; Messiou, Christina; Staudenherz, Anton; Berzaczy, Dominik; Schöder, Heiko

doi:10.1002/jmri.26848

Cited by 38 publications

(28 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This modality enables to reduce radiation exposure compared with 18 F‐FDG‐PET/CT, and it represents a valuable option especially in pediatric patients suffering from lymphoma. Besides the advantage of the high contrast resolution, MRI with the use of both DWI and PET findings allows to obtain a combined “functional” evaluation of cell density and metabolic activity . Indeed, the addition of DWI to PET/MRI is still debatable in lymphoma.…”

Section: Future Perspectivesmentioning

confidence: 99%

Whole‐body magnetic resonance imaging (WB‐MRI) in lymphoma: State of the art

Albano

Bruno

Patti

et al. 2019

Hematological Oncology

View full text Add to dashboard Cite

The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole‐body MRI (WB‐MRI) as a radiation‐free alternative to standard imaging procedures. WB‐MRI seems a less histology‐dependent functional imaging test than 18F‐fluorodeoxyglucose‐positron emission tomography/CT (18F‐FDG‐PET/CT). In patients with FDG‐avid lymphomas, such as diffuse large B‐cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), 18F‐FDG‐PET/CT remains the imaging reference standard for staging, with WB‐MRI potentially being a complementary modality that could replace CT, especially in young patients. On the other hand, WB‐MRI is a valuable imaging procedure for lymphoma surveillance and in lymphomas with variable/low FDG avidity and nonfollicular indolent lymphomas. The aim of this paper is to discuss the current state of the art of WB‐MRI in lymphoma by evaluating its diagnostic performance in different lymphoma subtypes: Hodgkin, aggressive, and indolent lymphomas.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

Whole‐body magnetic resonance imaging (WB‐MRI) in lymphoma: State of the art

Albano

Bruno

Patti

et al. 2019

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…68 Ga-Pentixafor uptake may possibly play a role as an independent parameter for detection and treatment response assessment in CLL patients. 1 , 73 …”

Section: The Utility Of Pet With Other Radio Tracers In Leukemiamentioning

confidence: 99%

“…68 Ga-Pentixafor uptake may possibly play a role as an independent parameter for detection and treatment response assessment in CLL patients. 1,73 11 C-Choline 11 C-Choline PET has been introduced for imaging various tumors, including prostate cancer, lung cancer and brain tumor. 74 The negligible uptake of 11 C-choline in the normal brain may be helpful for the diagnosis of extramedullary AL in brain.…”

Section: Staging and Response Assessment Of Leukemiamentioning

confidence: 99%

“…Other rare types include hairy cell leukemia (HCL), acute promyelocytic leukemia (APML) and T-cell prolymphocytic leukemia (T-PLL). 1 Acute leukemia (AL) has become a public health concern due to its increasing incidence rate and mortality rate. Therefore, its early diagnosis and treatment greatly contribute to the prognosis of leukemia patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Applications of PET in Diagnosis and Prognosis of Leukemia

Zhao

et al. 2020

Technol Cancer Res Treat

View full text Add to dashboard Cite

As a malignant hematopoietic stem cell disease, leukemia remains life-threatening due to its increasing incidence rate and mortality rate. Therefore, its early diagnosis and treatment play a very important role. In the present work, we systematically reviewed the current applications and future directions of positron emission tomography (PET) in patients with leukemia, especially 18F-FDG PET/CT. As a useful imaging approach, PET significantly contributes to the diagnosis and treatment of different types of leukemia, especially in the evaluation of extramedullary infiltration, monitoring of leukemia relapse, detection of Richter’s transformation (RT), and assessment of the inflammatory activity associated with acute graft versus host disease. Future investigations should be focused on the potential of PET/CT in the prediction of clinical outcomes in patients with leukemia and the utility of novel radiotracers.

show abstract

“…3,4 The CXCR4 chemokine receptor is a highly relevant biological target in the development of new diagnostics and therapies for cancers. [5][6][7][8][9] Nanoparticles targeting CXCR4 will allow the use of multimodal imaging to inform disease prognosis and improve treatment options. The use of superparamagnetic iron oxide nanoparticles allows T2 weighted MRI contrast and this can be combined with radiolabelling of the surface with radioisotopes for PET or SPECT imaging in the next phase of the research work.…”

mentioning

confidence: 99%